Download MendeleySelective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
Liu, Y.A., Jin, Q., Zou, Y., Ding, Q., Yan, S., Wang, Z., Hao, X., Nguyen, B., Zhang, X., Pan, J., Mo, T., Jacobsen, K., Lam, T., Wu, T.Y., Petrassi, H.M., Bursulaya, B., DiDonato, M., Gordon, W.P., Liu, B., Baaten, J., Hill, R., Nguyen-Tran, V., Qiu, M., Zhang, Y.Q., Kamireddy, A., Espinola, S., Deaton, L., Ha, S., Harb, G., Jia, Y., Li, J., Shen, W., Schumacher, A.M., Colman, K., Glynne, R., Pan, S., McNamara, P., Laffitte, B., Meeusen, S., Molteni, V., Loren, J.(2020) J Med Chem 63: 2958-2973
- PubMed: 32077280
- DOI: https://doi.org/10.1021/acs.jmedchem.9b01624
- Primary Citation of Related Structures:
6UIP - PubMed Abstract:
Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting β-cell proliferation could be one approach toward diabetes intervention. In this report we describe the discovery of a potent and selective DYRK1A inhibitor GNF2133, which was identified through optimization of a 6-azaindole screening hit. In vitro , GNF2133 is able to proliferate both rodent and human β-cells. In vivo , GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice. The work described here provides new avenues to disease altering therapeutic interventions in the treatment of type 1 diabetes (T1D).
Organizational Affiliation:
Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121, United States.
